TAmiRNA to present EV biodistribution technology at SelectBIO Congress Rotterdam

Biotech and diagnostic innovator TAmiRNA will make its debut at the SelectBIO Congress in The Netherlands, attending its Circulating Biomarkers and Extracellular Vesicles Europe 2024 conference.

The TAmiRNA presence at the conference is part of its focus on applications of extracellular vesicles (EVs) as biomarkers or therapies.

EV characterization services

TAmiRNA will showcase its services at Booth E5 in the Exhibition Zone at the Hilton Rotterdam.

Its displays will showcase the range of unique EV characterization services, such as transcriptomic analyses of both microRNAs (miRNAs), mRNAs, and long non-coding RNA sequences to academia and industry stakeholders working on diagnostic or therapeutic applications of EVs.

Biodistribution poster

The stand team including TAmiRNA founder and CEO/CSO, Dr. Matthias Hackl, and scientist Marianne Pultar, will also present its NextGen miND® data analysis pipeline and the interactive omics-data reports that it can generate.

TAmiRNA will also be a scientific contributor to the conference with a poster presentation on how to leverage extracellular vesicle microRNA cargo to enable in-vivo tracing of EVs based on their unique cargoes (biodistribution).

About TAmiRNA

TAmiRNA specializes in technologies for profiling levels of blood-circulating miRNAs and developing multi-parametric classification algorithms (“signatures”). TAmiRNA uses these technologies to develop minimal-invasive diagnostic tests for drug development, early diagnosis, and prognosis of disease, and as companion diagnostic tests to support treatment decisions. Through its CRO business, TAmiRNA enables clients from academic to private sectors to perform high-quality.

TAmiRNA is among Europe´s first companies that have CE-marked a microRNA-based test – hepatomiR® – which is intended for the diagnosis of liver function in liver cancer patients.

For its work on circulating microRNAs in bone disease, TAmiRNA is receiving funding from the European Union’s Horizon 2020 research and innovation program under the MARIE SKŁODOWSKA-CURIE grant agreement no. 860898. For TAmiRNA´s work on novel drug safety biomarkers, TAmiRNA receives funding from the Innovative Medicines Initiative 2 Joint Undertaking “TransBioLine” under grant agreement No. 821283. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. For its work on senescence-associated biomarkers, TAmiRNA is receiving funding from Eureka-Eurostars grant Ab-SENS. For its work on novel liver function biomarkers, TAmiRNA is receiving funding from the Vienna Business Agency as well as FFG.

More information available at: www.tamirna.com

About SelectBIO Congress 2024

The annual Circulating Biomarkers & Extracellular Vesicles Europe Conference brings together academics and industry participants from around the world focused on research, biomarker analyses and therapeutics development leveraging the cargo from various classes of circulating biomarkers including cfDNA, CTCs as well as Exosomes and Extracellular Vesicles (EVs).

A key focus area for the conference is development of Liquid Biopsies utilizing circulating cell-free DNA (cfDNA), circulating tumor cells (CTCs) and other biomarkers found in biofluids and the use of tools & technologies from related disciplines to enable this.

The conference is part of the SelectBIO Congress now in its 16th year that has expanded to comprise four co-located and concurrent conference tracks, also including the LOAC & Microfluidics Europe 2024 Conference, Point-of-Care, Biosensors & Mobile Diagnostics Europe 2024, and Organoids and Spheroids Europe 2024.

The Congress is a two-day event opening June 24 at the Hilton Rotterdam, in The Netherlands. The conferences will reflect extensive international perspectives, with speakers, poster presentations, sponsors, and exhibitors drawn from Europe, North America, and Asia/Pacific. The co-located exhibition will cover latest technological advances and associated products and services from leading solution providers from around the world.

The event is organized by CAAT-Europe with further information at: https://selectbiosciences.com/conferences


Click on TAmiRNA EV characterization services to learn more.
Click on TAmiRNA miND® spike-ins for small RNA-sequencing for further information.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.